The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases-Reference-Cited by-同舟云学术

The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases

Published:2009-01 Issue:6 Volume:48 Page:927-931
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Desar Ingrid M. E.¹,Mulder Sasja F.¹,Stillebroer Alexander B.²,van Spronsen Dick-Johan³,van der Graaf Winette T. A.¹,Mulders Peter F. A.²,van Herpen Carla M. L.¹

Affiliation:

1. Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

2. Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

3. Department of Internal Medicine, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands

Publisher

Informa UK Limited

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/02841860902974167

Reference12 articles.

1. Flare-up: An often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors

2. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhanced anti-tumor therapy for hepatocellular carcinoma via sorafenib and KIAA1199-siRNA co-delivery liposomes;Saudi Pharmaceutical Journal;2024-09

2. Critical role of miR-21/exosomal miR-21 in autophagy pathway;Pathology - Research and Practice;2024-05

3. MiR-21-5p promotes sorafenib resistance and hepatocellular carcinoma progression by regulating SIRT7 ubiquitination through USP24;Life Sciences;2023-07

4. Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation;Cell Death & Disease;2022-09-22

5. Tumours modulate the systemic vascular response to anti‐angiogenic therapy;Journal of Applied Toxicology;2022-03-02